Delivering quality therapy since 1901

Scientific posters

Barabassy_EPA 2018_poster 18-0626.jpg 
Hormonal Effects of Cariprazine: Post Hoc Analysis of Pooled Data from Schizophrenia Studies for Sexual Dysfunction and Prolactin Changes
by Ágota Barabassy, Balázs Szatmári, István Laszlovszky, Judit Harsányi, Anna Burján, Dorottya Réti-Győrffy, Willie Earley, Mehul Patel, György Németh

Laszlovszky_EPA 2018_poster 18-0614.jpg
Improvement of Schizophrenia Social Amotivation and Expressive Deficits Over Time After Cariprazine and Risperidone Treatment: Post Hoc Analysis of a Phase-3 Trial
by István Laszlovszky, Ágota Barabássy, Balázs Szatmári, Judit Harsányi, Erzsébet Szalai, György Németh

Szatmári_EPA 2018_poster 18-0634.jpg
Efficacy of Cariprazine in Predominant Negative Symptomps of Schizophrenia - Post Hoc Analyses Against Different Comparators
by Balázs Szatmári, Ágota Barabássy, István Laszlovszky, Judit Harsányi, Dorottya Réti-Győrffy, Károly Acsai, Willie Earley, Mehul Patel, György Németh

Barabassy_P616_ECNP 2018.jpg
Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole
by Ágota Barabassy, Balázs Szatmári, István Laszlovszky, Judit Harsányi, Károly Acsai, Barbara Sebe, Willie Earley, Mehul Patel, György Németh

Laszlovszky_P592_ECNP 2018.jpg
Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms
by István Laszlovszky, Ágota Barabassy, Béla Kiss, Balázs Szatmári, Nika Adham, Willie Earley, György Németh

Szatmari_P618_ECNP 2018.jpg
Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies
by Balázs Szatmári, Agota Barabassy, István Laszlovszky, Judit Harsányi, Károly Acsai, Anna Burján, Barbara Sebe, Willie Earley, Mehul Patel, György Németh1